Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.

Humans Leukemia, Myeloid, Acute / drug therapy Hematopoietic Stem Cell Transplantation Prognosis Recurrence
AML Molecular patterns Relapse Selinexor

Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 24 08 2022
accepted: 07 12 2022
pubmed: 29 12 2022
medline: 3 2 2023
entrez: 28 12 2022
Statut: ppublish

Résumé

Relapse in patients with acute myeloid leukemia (AML) is common and is associated with a dismal prognosis. Treatment options are limited and the understanding of molecular response patterns is still challenging. We analyzed the clonal response patterns of 15 patients with relapsed/refractory AML treated with selinexor in a phase II trial (SAIL). DNA was analyzed at three time points and showed a decline of mutated alleles in FLT3, SF3B1, and TP53 under SAIL treatment. Overall survival (OS) was similar between patients with declining versus persisting clones. We show an interesting long-term course of a patient who relapsed after allogeneic stem cell transplantation (alloHCT) with SF3B1- and SRSF2-mutated AML and received selinexor as maintenance treatment for 4 years. Measurable residual disease (MRD) remained detectable for 2 weeks after donor lymphocyte infusion (DLI) in this patient and then remained negative under selinexor maintenance treatment. Selinexor was tolerated well and was stopped after 4 years of SAIL treatment. We present an exploratory study and identify subclonal patterns of patients treated with selinexor.

Identifiants

DOI: 10.1007/s00277-022-05075-4 PMID: 36576532 PMC: PMC9889470
pubmed: 36576532
doi: 10.1007/s00277-022-05075-4
pii: 10.1007/s00277-022-05075-4
pmc: PMC9889470
doi:

Substances chimiques

selinexor 31TZ62FO8F

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-328

Informations de copyright

© 2022. The Author(s).

Références

Ann Hematol. 2021 Feb;100(2):499-503
pubmed: 33108522
J Hematol Oncol. 2018 Jan 05;11(1):4
pubmed: 29304833
Blood. 2017 Jun 15;129(24):3165-3174
pubmed: 28336527
Br J Haematol. 2020 Aug;190(3):e169-e173
pubmed: 32515072
Blood. 2018 Oct 18;132(16):1703-1713
pubmed: 30190321
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Mol Hum Reprod. 2011 Jun;17(6):335-43
pubmed: 21177337
Drugs. 2019 Sep;79(13):1485-1494
pubmed: 31429063
Leuk Lymphoma. 2020 Feb;61(2):387-396
pubmed: 31545113
Clin Lymphoma Myeloma Leuk. 2018 May;18(5):335-345
pubmed: 29610030
Haematologica. 2018 Oct;103(10):1642-1653
pubmed: 29773601
Nature. 2018 Oct;562(7728):526-531
pubmed: 30333627
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Biochem Pharmacol. 2012 Apr 15;83(8):1021-32
pubmed: 22209898
Ann Hematol. 2017 Aug;96(8):1361-1372
pubmed: 28612220
Leuk Lymphoma. 2021 Dec;62(13):3192-3203
pubmed: 34323164
Am J Hematol. 2021 Apr 1;96(4):462-470
pubmed: 33502020
Blood. 2012 Apr 12;119(15):3578-84
pubmed: 22389253
Clin Cancer Res. 2016 Dec 15;22(24):6142-6152
pubmed: 27358488
J Clin Oncol. 2016 Dec;34(34):4094-4101
pubmed: 27507877

Auteurs

Piroska Klement (P)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Walter Fiedler (W)

Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Razif Gabdoulline (R)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Louisa-Kristin Dallmann (LK)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Clara Philine Wienecke (CP)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Johannes Schiller (J)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Christian Kandziora (C)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Katrin Teich (K)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Bennett Heida (B)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Konstantin Büttner (K)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Maximilian Brandes (M)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Carolin Funke (C)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Martin Wichmann (M)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Basem Othman (B)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Joerg Chromik (J)

Medical Clinic II, Hematology, Hemostaseology, Medical Oncology, Rheumatology, Infectious Disease, University Hospital Frankfurt, Frankfurt, Germany.

Stefanie Amberg (S)

GSO Global Clinical Research B.V., Amsterdam, The Netherlands.

Maxim Kebenko (M)

Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Vera Schlipfenbacher (V)

Medical Clinic II, Hematology, Hemostaseology, Medical Oncology, Rheumatology, Infectious Disease, University Hospital Frankfurt, Frankfurt, Germany.

Anne Christine Wilke (AC)

Medical Clinic II, Hematology, Hemostaseology, Medical Oncology, Rheumatology, Infectious Disease, University Hospital Frankfurt, Frankfurt, Germany.

Franziska Modemann (F)

Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mildred Scheel Cancer Career Center, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Melanie Janning (M)

Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Hubert Serve (H)

Medical Clinic II, Hematology, Hemostaseology, Medical Oncology, Rheumatology, Infectious Disease, University Hospital Frankfurt, Frankfurt, Germany.

Carsten Bokemeyer (C)

Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Susann Theile (S)

GSO mbH, Hamburg, Germany.

Ute Deppermann (U)

GSO Global Clinical Research B.V., Amsterdam, The Netherlands.

Anne L Kranich (AL)

GSO mbH, Hamburg, Germany.

Arnold Ganser (A)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Felicitas Thol (F)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany.

Michael Heuser (M)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany. heuser.michael@mh-hannover.de.
ORCID: 0000-0001-5318-9044

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Molecular response patterns in...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Molecular response patterns in...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Molecular response patterns in...
questionsmedicales.fr › Diagnostic › Pronostic › Molecular response patterns in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › Molecular response patterns in...